Columns

Drugs & Children
Inflammatory bowel disease and biosimilars
Over the last 20 years, biological drugs have changed the therapeutic prospect for chronic inflammatory bowel diseases both in the adult and in the child.1 Infliximab was the first drug that, when its patent expired, had biosimilars authorised by EMA, CT-P13 and SB2 respectively in 2013 and 2016.2...
[more]
Drugs & Elderly
Anticholinergic drugs in the elderly patients
Focus Farmacovigilanza 2017;97(6):1
Many drugs commonly used in the clinical practice have an anticholinergic activity. These are mostly psychotropic drugs like tricyclic antidepressants and antipsychotics, but also drugs that target other organs and apparatus, like for example first generation antihistaminics or furosemide (see...
[more]
Drugs & Pregnancy
The quality of the information in the Summary of the Product Characteristics
Focus Farmacovigilanza 2017;96(3):1
The Summary of the Product Characteristics (SPC) represents the source of official and legitimate drug information for the healthcare professionals within the European Union. Specific information concerning the use in pregnancy, breastfeeding and fertile age, besides the effects on fertility, are...
[more]
Phytovigilance & Supplements
Safety of Ganoderma lucidum supplements
Focus Farmacovigilanza 2016;95(11):11
The use of natural products is a growing phenomenon both in Italy and in the rest of the world. Some mushrooms have been used by the Eastern traditional medicine for centuries to improve the general health, increase the immune defenses and as adjuvant for the treatment of chronic diseases. The...
[more]
Drugs & Children
NSAIDs, pneumonia and empyema: an ongoing confrontation
Focus Farmacovigilanza 2016;94(9):2
Over the past twenty years, the worldwide increase in cases of pleural empyema and complicated pneumonia by Streptococcus pneumoniae in children has attracted much epidemiological and clinical attention.1 In fact, particularly invasive and/or pathogenic serotypes have emerged – especially serotypes...
[more]
Drugs & Elderly
Metformin in the diabetic elderly patient: an old, safe and effective treatment
Focus Farmacovigilanza 2016;93(3):7
Over-65 diabetics represent about half of the patients visiting general practitioners. Although diabetes pathogenesis in geriatric and young age are similar, treatment gold standards and clinical conditions are extremely variable, requiring a more individualised approach.1 In this context, a...
[more]
Drugs & Pregnancy
Pharmacovigilance and reproductive health: the Italian contribute to the results of the EUROmediCAT project
Focus Farmacovigilanza 2016;92(1):9
EUROmediCAT – “Safety of medication use in pregnancy”, a project of the Seventh Framework Programme for Research and Technical Development funded by the European Union in the period 2011-2015, experimented integrating “traditional” registers for congenital anomalies with other already existing...
[more]
Phytovigilance & Supplements
Herbs and drugs: friends, enemies or allies against cancer?
Focus Farmacovigilanza 2015;91(11):6
The topic of interactions between oncologic drugs and natural products has been recently at the heart of two events organized by the Project Convivio at the Oncology Unit of the Hospital of Verona, with the participation of oncological out-patients, and of another event on nutrition and cancer held...
[more]
Drugs & Children
Drugs and gastroesophageal reflux: not always effective and with some risks
Focus Farmacovigilanza 2015;90(9):7
Paediatricians have always dedicated great attention and several diagnostic-therapeutic tools in order to tackle the gastroesophageal reflux, especially in early childhood. The most recent literature has scaled down the problem, attributing the gastroesophageal reflux to its paraphysiological...
[more]
Drugs & Elderly
The gap between guidelines and daily practice
Focus Farmacovigilanza 2015;89(8):6
Appropriate prescription of drugs in elderly patients is one of the biggest current challenges in clinical geriatrics. As is already known, the elderly often have multiple concomitant chronic conditions (multi-morbidities), which require the simultaneous use of multiple drugs (polypharmacy), which...
[more]

Pages

Archivio news